World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
33870
World Ranking
13501
National Ranking
6866

Overview

Gini F. Fleming is affiliated with the University of Chicago in the United States. Their research spans multiple areas within medicine, focusing predominantly on oncology and biochemistry, genetics, and molecular biology. Fleming has contributed extensively to the fields of oncology, reproductive medicine, pulmonary and respiratory medicine, cancer research, and obstetrics and gynecology.

Their main topics of research include ovarian cancer diagnosis and treatment, endometrial and cervical cancer treatments, breast cancer treatment studies, estrogen and related hormone effects, cancer immunotherapy and biomarkers, advanced breast cancer therapies, and PARP inhibition in cancer therapy.

Fleming's frequent publication venues highlight a concentration in clinical oncology and gynecologic oncology, with numerous articles published in the following journals:

  • Journal of Clinical Oncology
  • Gynecologic Oncology
  • Cancer Research
  • Annals of Oncology
  • Breast Cancer Research and Treatment

The following papers are among the recent publications associated with Fleming, demonstrating involvement in clinical trials and translational cancer research:

  • Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment (2020), published in Obstetrics and Gynecology
  • Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209) (2020), published in Journal of Clinical Oncology
  • Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial (2021), published in The Lancet
  • Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials (2022), published in Journal of Clinical Oncology
  • Epigenetic priming enhances antitumor immunity in platinum-resistant ovarian cancer (2022), published in Journal of Clinical Investigation

Fleming has collaborated frequently with several researchers, including Rita Nanda, Olufunmilayo I. Olopade, Meredith M. Regan, Prudence A. Francis, and John W. Moroney, indicating a strong network within clinical and translational oncology research.

Best Publications

  • Incorporation of bevacizumab in the primary treatment of ovarian cancer

    Robert A. Burger;Mark F. Brady;Michael A. Bookman;Gini F. Fleming

  • Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

    I. Craig Henderson;Donald A. Berry;George D. Demetri;Constance T. Cirrincione

  • Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*

    Abram Recht;Stephen B. Edge;Lawrence J. Solin;David S. Robinson

  • UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

    L Iyer;S Das;L Janisch;M Wen

  • Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer

    Olivia Pagani;Meredith M. Regan;Barbara A. Walley;Gini F. Fleming

  • Adjuvant ovarian suppression in premenopausal breast cancer

    Prudence A. Francis;Prudence A. Francis;Meredith M. Regan;Gini F. Fleming;István Láng

  • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    Robert L. Coleman;Gini F. Fleming;Mark F. Brady;Elizabeth M. Swisher

  • Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia

    Agustin A. Garcia;Hal Hirte;Gini Fleming;Dongyun Yang

  • Phase III Trial of Doxorubicin Plus Cisplatin With or Without Paclitaxel Plus Filgrastim in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

    Gini F. Fleming;Virginia L. Brunetto;David Cella;Katherine Y. Look

  • Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study

    Joyce F. Liu;William T. Barry;Michael Birrer;Jung Min Lee

  • Barriers to Clinical Trial Participation by Older Women With Breast Cancer

    M. Margaret Kemeny;Bercedis L. Peterson;Alice B. Kornblith;Hyman B. Muss

  • Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies.

    Arno J Mundt;Anthony E Lujan;Jacob Rotmensch;Steven E Waggoner

  • Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.

    P. A. Francis;P. A. Francis;O. Pagani;G. F. Fleming;B. A. Walley

  • Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.

    Jason J. Luke;Jeffrey M. Lemons;Theodore G. Karrison;Sean P. Pitroda

  • Current recommendations and recent progress in endometrial cancer.

    Rebecca A. Brooks;Rebecca A. Brooks;Gini F. Fleming;Ricardo R. Lastra;Nita K. Lee

  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

    Kathleen N Moore;Angeles Alvarez Secord;Melissa A Geller;David Scott Miller

  • Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update

    Abram Recht;Elizabeth A. Comen;Richard E. Fine;Gini F. Fleming

  • Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342

    Eric P. Winer;Donald A. Berry;Susan Woolf;David Duggan

  • Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer

    Krishnansu S. Tewari;Robert A. Burger;Danielle Enserro;Barbara M. Norquist

  • Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study.

    Gini F. Fleming;Michael W. Sill;Michael W. Sill;Kathleen M. Darcy;D. Scott McMeekin

Frequent Co-Authors

Mark J. Ratain
Mark J. Ratain University of Chicago
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Ursula A. Matulonis
Ursula A. Matulonis Harvard University
Michael J. Birrer
Michael J. Birrer University of Arkansas for Medical Sciences
Meredith M. Regan
Meredith M. Regan Harvard University
Alan S. Coates
Alan S. Coates University of Sydney
Olufunmilayo I. Olopade
Olufunmilayo I. Olopade University of Chicago
Bradley J. Monk
Bradley J. Monk University of Arizona
Richard D. Gelber
Richard D. Gelber Harvard University
Theodore Karrison
Theodore Karrison University of Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a future in medicine doesn’t always mean attending traditional, on-campus programs. For those interested in nursing, there are several flexible options, such as the cheapest bsn programs available online. These programs provide an affordable pathway for registered nurses seeking career advancement without the financial strain.

Not from a nursing background? Opportunities still exist through direct entry msn programs for non-nursing majors online, allowing those with different undergraduate degrees to shift into nursing quickly.

Applicants concerned about admissions requirements should consider some of the easiest nursing schools to get into, which can help streamline entry into competitive healthcare fields.

For those seeking careers outside of direct patient care, medical billing and coding online schools offer accredited training opportunities with financial aid, preparing graduates for essential roles in healthcare administration.

Best Scientists Citing Gini F. Fleming

Trending Scientists

Recently Published Articles